Journal of Neuro-Oncology

, Volume 54, Issue 2, pp 139–150 | Cite as

Current management of prolactinomas

  • Panos Nomikos
  • Michael Buchfelder
  • Rudolf Fahlbusch


Prolactinomas constitute the largest group of pituitary adenomas in autopsy series. However, their relative incidence in recent surgical series is much less impressive since medical treatment with dopamine agonists is routinely employed, which in many cases leads to tumor shrinkage and normalization of prolactin levels. The clinical symptoms of hyperprolactinemia are menstrual dysfunction and galactorrhea in women and loss of libido and potency in men. Prolactinomas may present also as space occupying sellar mass lesions impinging on the adjacent structures like the pituitary gland, cavernous sinus and optic nerves. The standard primary treatment is medical by dopamine agonists. Prolactinomas are the prototype of tumors, the growth of which can be reliably and safely inhibited by specific drugs other than cytostatic chemotherapy. These unfortunately have side effects, like orthostatic hypotension, nausea and vomiting. The effects induced by dopamine agonists are suppressive but not tumoricidal. Thus, the therapeutic effect is only maintained as long as the drug is administered. Consequently, in most cases, treatment has to be continued life-long with a few exceptions, in whom normoprolactinemia persists even after discontinuation of dopamine agonists. Main indications of surgery in prolactinomas are intolerance of the medication, and tumors not responding to dopamine agonists. Occasionally, these may ultimately require radiation therapy. nobreak Remission rates in large series of surgically treated prolactinomas vary between 54% and 86%. In our consecutive series of 540 surgically treated prolactinomas, the normalization rate after transsphenoidal surgery basically depended on the preoperative prolactin levels, tumor size and extension. The remission rate of 82% in microprolactinomas with initial prolactin levels < 200ng/ml would even in small adenomas make one consider surgical treatment as an interesting alternative to long-term medical treatment.

prolactinoma pituitary adenoma medical treatment surgical management 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K: Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 304: 156–158, 1981Google Scholar
  2. 2.
    Riedel M, Noldus J, Saeger W, Ludecke DK: Sellar lesions associated with isolated hyperprolactinaemia. Morphological, immunocytochemical, hormonal and clinical results. Acta Endocrinol (Copenh.) 113: 196–203, 1986Google Scholar
  3. 3.
    Hardy J: Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT (eds) Diagnosis and Treatment of Pituitary Tumors. Excerpta Media, Amsterdam, 1972, pp 179–194Google Scholar
  4. 4.
    Besser GM, Parke L, Edwards CRW, Forsythe IA, MacNeilly AS: Galactorrhea; successful treatment with reduction of plasma prolactin levels by bromocriptine. Br Med J 2: 669–672, 1972Google Scholar
  5. 5.
    Nillius SJ, Bergh T, Larsson SG: Pituitary tumors and pregnancy. In: Derome P, Jedynak CP, Peillon F (eds) Second European Workshop on Pituitary Adenomas. Asclepios France, Paris, 1980, pp 103–112Google Scholar
  6. 6.
    Veldhuis JD, Johnson ML: Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab 67: 116–123, 1988Google Scholar
  7. 7.
    Thorner MO, Vance ML, Horvath E, Kovacs K: The anterior pituitary. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology. WB Saunders, Philadelphia, 1992, pp 221–311Google Scholar
  8. 8.
    Lechan RM: Neuroendocrinology of pituitary hormone regulation. Endocrinol Metab Clin North Am 16: 475–501, 1987Google Scholar
  9. 9.
    Nikolics K, Mason AJ, Szonyi E, Ramachandran J, Seeburg PH: A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature 316: 511–517, 1985Google Scholar
  10. 10.
    O'Brien T, O'Riordan DS, Gharib H, Scheithauer BW, Ebersold MJ, van Heerden JA: Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 39: 273–278, 1996Google Scholar
  11. 11.
    Thapar K, Kovacs K, Laws ER: The classification and molecular biology of pituitary adenomas. Adv Tech Stand Neurosurg 22: 4–53, 1995Google Scholar
  12. 12.
    Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S: Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 71: 1427–1433, 1990Google Scholar
  13. 13.
    Bystrom C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, Oberg K, Werner S, Nordenskjold M: Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 87: 1968–1972, 1990Google Scholar
  14. 14.
    Heitz PU, Kloppel G, Polak JM, Staub JJ: Ectopic hormone production by endocrine tumors: localization of hormones at the cellular level by immunocytochemistry. Cancer 48: 2029–2037, 1981Google Scholar
  15. 15.
    Park SK, Keanan MW, Selmanoff M: Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated rats. Neuroendocrinology 58: 448–453, 1993Google Scholar
  16. 16.
    Polson DW, Sagle M, Mason HD, Adams J, Jacobs HS, Franks S: Ovulation and normal luteal function during LHRHtreatment ofwomen with hyperprolactinaemic amenorrhoea. Clin Endocrinol (Oxf) 24: 531–537, 1986Google Scholar
  17. 17.
    Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V: Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67: 124–130, 1988Google Scholar
  18. 18.
    Onoda N, Kamezu Y, Takagi S, Shinohara Y, Osamura RY: An autopsy case of invasive pituitary adenoma (prolactinoma) with rapid fatal clinical course due to streptococcal meningitis. Acta Pathol Jpn 42: 832–836, 1992Google Scholar
  19. 19.
    Molitch ME: Diagnosis and treatment of prolactinomas. Adv Intern Med 44: 117–153, 1999Google Scholar
  20. 20.
    De Marinis L, Mancini A, Maira G, Anile C, Menini E, Barbarino A: Postoperative evaluation of dopaminergic tone in prolactinoma patients. II. Plasma thyrotropin response to metoclopramide. J Clin Endocrinol Metab 58: 405–409, 1984Google Scholar
  21. 21.
    Persani L, Beck-Peccoz P, Medri G, Conti A, Faglia G: Thyrotropin alpha-and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas. Neuroendocrinology 53: 411–415, 1991Google Scholar
  22. 22.
    Scanlon MF, Peters JR, Salvador J, Richards SH, John R, Howell S, Williams ED, Thomas JP, Hall R: The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. Clin Endocrinol (Oxf) 24: 435–446, 1986Google Scholar
  23. 23.
    Knosp E, Steiner E, Kitz K, Matula C: Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610–617, 1993Google Scholar
  24. 24.
    Buchfelder M, Fahlbusch R, Nomikos P, et al.: Recent advances in CT and MRI in the diagnosis and followup of hypothalamo-pituitary disease. In: von Werder K, Fahlbusch R (eds) Pituitary Adenomas. Excerpta Medica Elsevier, Amsterdam, 1996, pp 132–145Google Scholar
  25. 25.
    March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR: Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139: 835–844, 1981Google Scholar
  26. 26.
    Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A: The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412–418, 1989Google Scholar
  27. 27.
    Weiss MH, Teal J, Gott P, Wycoff R, Yardley R, Apuzzo MLJ, Giannota SL, Kletzky O, March C: Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12: 180–183, 1983Google Scholar
  28. 28.
    DelPozo E, Del Re RB, Varga L, Friesen H: The inhibition of prolactin secretion in man by CB-154 (2-Br-alphaergocryptine). J Clin Endocrinol Metab 35: 768–771, 1972Google Scholar
  29. 29.
    Spark RF, Baker R, Bienfang DC, Bergland R: Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery? JAMA 247: 311–316, 1982Google Scholar
  30. 30.
    De Cecco L, Foglia G, Ragni N, Rossato P, Venturini PL: The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: clinical and hormonal responses. Clin Endocrinol (Oxf) 9: 491–498, 1978Google Scholar
  31. 31.
    Franks S, Horrocks PM, Lynch SS, Butt WR, London DR: Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment. Lancet 2: 659–661, 1981Google Scholar
  32. 32.
    Dallabonzana D, Liuzzi A, Oppizzi G, Cozzi R, Verde G, Chiodini P, Rainer E, Dorow R, Horowski R: Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab 63: 1002–1007, 1986Google Scholar
  33. 33.
    Dall'Ara A, Lima L, Cocchi D, Di Salle E, Cancio E, Devesa J, Muller EE: Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary. Eur J Pharmacol 151: 97–102, 1988Google Scholar
  34. 34.
    Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A: Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63: 941–945, 1986Google Scholar
  35. 35.
    Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE, Miller MM, Molitch ME: CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 68: 336–339, 1989Google Scholar
  36. 36.
    Rasmussen C, Bergh T, Wide L, Brownell J: CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 26: 321–326, 1987Google Scholar
  37. 37.
    Maurer RA: Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J Biol Chem 255: 8092–8097, 1980Google Scholar
  38. 38.
    Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698–705, 1985Google Scholar
  39. 39.
    Tindall GT, Kovacs K, Horvath E, Thorner MO: Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55: 1178–1183, 1982Google Scholar
  40. 40.
    Landolt AM, Osterwalder V: Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179–1183, 1984Google Scholar
  41. 41.
    Bevan JS, Adams CB, Burke CW, Morton KE, Molyneux AJ, Moore RA, Esiri MM: Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol (Oxf) 26: 541–556, 1987Google Scholar
  42. 42.
    Landolt AM, Keller PJ, Froesch ER, Mueller J: Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2: 657–658, 1982Google Scholar
  43. 43.
    Vance ML, Thorner MO: Prolactinomas. Endocrinol Metab Clin North Am 16: 731–753, 1987Google Scholar
  44. 44.
    Molitch ME: Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 21: 877–901, 1992Google Scholar
  45. 45.
    Bevan JS, Webster J, Burke CW, Scanlon MF: Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 220–240, 1992Google Scholar
  46. 46.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69: 500–509, 1989Google Scholar
  47. 47.
    Klijn JG, Lamberts SW, Birkenhager JC: TRH test for prolactinoma. Lancet 2: 581–582, 1979Google Scholar
  48. 48.
    Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6): 2247–2252; 85: 2247-2252, 2000Google Scholar
  49. 49.
    Nomikos P, Fahlbusch R, Buchfelder M: Macroprolactinomas: Persistent normoprolactinemia and disappearence of tumour on MR images after short-term medical treatment with dopamine agonists. Exp Clin Endocrinol Diabetes 108: 193–2000Google Scholar
  50. 50.
    Hildebrandt G, Zierski J, Christophis P, Laun A, Schatz H, Lancranjan I, Klug N: Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma. Acta Neurochir (Wien) 96: 107–113, 1989Google Scholar
  51. 51.
    Holness RO, Shlossberg AH, Heffernan LP: Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma. Neurology 34: 111–113, 1984Google Scholar
  52. 52.
    Webster J: Cabergoline and quinagolide therapy for prolactinomas. Clin Endocrinol (Oxf) 53(5): 549–550; 53: 549-550, 2000Google Scholar
  53. 53.
    Landolt AM: Prolactinomas: preoperative bromocriptine treatment. Surgical results. In: Barrow DL (eds) Perspectives in Neurological Surgery. Quality Medical Publishing, St. Louis, 1990, pp 105–115Google Scholar
  54. 54.
    Fahlbusch R, Buchfelder M: Surgical complications. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, NewYork, 1996, pp 395–408Google Scholar
  55. 55.
    Laws ER, Kern EB: Complications of trans-sphenoidal surgery. Clin Neurosurg 23: 401–416, 1976Google Scholar
  56. 56.
    Zervas NT: Surgical results for pituitary adenomas: Results of an international survey. In: Black PM, Zervas NT, Ridgway EC, Martin JB (eds) Secretor Tumors of the Pituitary Gland. Raven Press, New York, 1984, pp 377–385Google Scholar
  57. 57.
    Faria MA, Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg 56: 33–43, 1982Google Scholar
  58. 58.
    Domingue JN, Richmond IL, Wilson CB: Results of surgery in 114 patients with prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 137: 102–108, 1980Google Scholar
  59. 59.
    Aubourg PR, Derome PJ, Peillon F, Jedynak CP, Visot A, Le Gentil P, Balagura S, Guiot G: Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: prolactin levels and tumor size as predicting factors. Surg Neurol 14: 141–143, 1980Google Scholar
  60. 60.
    Hardy J, Beauregard H, Robert F: Prolactin-secreting pituitary adenomas: transsphenoidal microsurgical treatment. In: Robyn C, Harter M (eds) Progress in Prolactin Physiology and Pathology. Elsevier/North-Holland Biomedical Press, Amsterdam, 1978, pp 361–370Google Scholar
  61. 61.
    Ahmadi J, North CM, Segall HD, Zee CS, Weiss MH: Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol 146: 257–262, 1986Google Scholar
  62. 62.
    Buchfelder M, Fahlbusch R, Adams EF, Kiesewetter F, Thierauf P: Proliferation parameters for pituitary adenomas. Acta Neurochir Suppl (Wien) 65: 18–21, 1996Google Scholar
  63. 63.
    Barrow DL, Mizuno J, Tindall GT: Management of prolactinomas associated with very high serum prolactin levels. J Neurosurg 68: 554–558, 1988Google Scholar
  64. 64.
    Faglia G, Moriondo P, Travaglini P, Giovanelli MA: Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet 1: 133–134, 1983Google Scholar
  65. 65.
    Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A: Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol Res Pract 187: 587–592, 1991Google Scholar
  66. 66.
    Fahlbusch R, Buchfelder M, Schrell U: Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J Neurosurg 807–815, 1987Google Scholar
  67. 67.
    Fahlbusch R, Giovanelli M, Crosignani P, Faglia G, Rjosk HK, von Werder K: Differentiated therapy of microprolactinomas: Significance of transsphenoidal adenomectomy. In: Faglia G, Giovanelli M, McLeod R (eds) Pituitary Microadenomas. Academic Press, London, 1980, pp 443–457Google Scholar
  68. 68.
    Tucker HS, Grubb SR, Wigand JP, Taylon A, Lankford HV, Blackard WG, Becker DP: Galactorrhea-amenorrhea syndrome: follow-up of forty-five patients after pituitary tumor removal. Ann Intern Med 94: 302–307, 1981Google Scholar
  69. 69.
    Serri O, Rasio E, Beauregard H, Hardy J, Somma M: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309: 280–283, 1983Google Scholar
  70. 70.
    Fahlbusch R, Buchfelder M: Present status of neurosurgery in the treatment of prolactinomas. Neurosurg Rev 8: 195–205, 1985Google Scholar
  71. 71.
    Laws ER, Chenelle AG, Thapar K: Recurrence after transsphenoidal surgery for pituitary adenomas. In: Fahlbusch R, von Werder K (eds) Pituitary Adenomas: From Basic Research to Diagnosis and Therapy. Elsevier, Amsterdam, 1996, pp 3–9Google Scholar
  72. 72.
    Rush SC, Newall J: Pituitary adenoma: the efficacy of radiotherapy as the sole treatment. Int J Radiat Oncol Biol Phys 17: 165–169, 1989Google Scholar
  73. 73.
    Tsagarakis S, Grossman A, Plowman PN, Jones AE, Touzel R, Rees LH, Wass JA, Besser GM: Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol (Oxf) 34: 399–406, 1991Google Scholar
  74. 74.
    Grossman A, Besser M, Wass J, Rees L: Treatment of prolactinomas with megavoltage radiotherapy. Br Med J (Clin Res Ed) 288: 2002–1984Google Scholar
  75. 75.
    Landolt AM, Lomax N: Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(3): 14–18, 2000Google Scholar
  76. 76.
    Molitch ME: Pregnancy and the hyperprolactinemicwoman. N Engl J Med 312: 1364–1370, 1985Google Scholar
  77. 77.
    Krupp P, Monka C: Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823–827, 1987Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Panos Nomikos
    • 1
  • Michael Buchfelder
    • 1
  • Rudolf Fahlbusch
    • 1
  1. 1.Department of NeurosurgeryUniversity of Erlangen-NürnbergErlangenGermany

Personalised recommendations